32 views 0 likes

Dr. CCHMC Pediatric Surgery

GCMD Space · View profile →

Update Course Rewind: Management of Recurrent Pancreatitis

Video Published 2024-05-28 Updated 2026-08-01

Timestops (4)

Recurrent Pancreatitis Case Presentation

Genetic Testing and Mutation Analysis

Imaging and Diagnostic Workup

Treatment Strategy and Endoscopic Management

Topic Overview

A pediatric surgery educational discussion on managing recurrent pancreatitis in children, centered on a case of a 7-year-old with acute recurrent pancreatitis who has undergone 7 ERCPs. The discussion emphasizes the critical role of genetic testing before surgical intervention, as genetic mutations (particularly PRSS1) alter treatment strategy away from drainage procedures toward total pancreatectomy with islet autotransplantation (TPIAT). Key clinical points include the risk of islet cell loss with repeated pancreatitis attacks, the limitations of endoscopic therapy in genetically-driven disease, and conservative management of asymptomatic fluid collections.

Key Takeaways

Obtain genetic panel (PRSS1, CTRC, CFTR) after first severe or second episode of acute pancreatitis to guide treatment decisions.
Avoid Frey procedure in genetic mutations—resection loses islet cells without preventing ongoing parenchymal attacks from mutation.
Refer for TPIAT evaluation when endoscopic management fails rather than continuing multiple ERCPs that risk further islet cell loss.
Drain pancreatic fluid collections only if symptomatic (pain, gastric outlet obstruction); asymptomatic collections self-resolve.
MRCP with T2 sequences is best non-invasive imaging; ERCP is therapeutic not diagnostic after initial workup.

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Speaker 1 — host
Cecilia Gena — host
Juan Gurria — guest
Speaker 4
Speaker 5
Speaker 6

Chapters

0:01Case Presentation and Initial Management Options — Introduction of a 7-year-old with acute recurrent pancreatitis, 7 prior ERCPs, and pancreatic duct stricture. Audience polled on management approach including repeat ERCP, genetic testing, or Frey procedure.
1:28Role of Genetics in Treatment Planning — Discussion of genetic mutations in pancreatitis (PRSS1, CTRC, CFTR, CPA1) and how genetic findings alter surgical approach. Explanation of why Frey procedure may be inappropriate in genetic pancreatitis due to ongoing parenchymal attacks and islet cell loss.
3:37Timing of Referral and Imaging Strategies — Guidance on when to refer for specialized care, role of endoscopic management, and imaging modalities including ultrasound, CT, MRCP with T2 sequences, and endoscopic ultrasound.
5:11Fluid Collections and Summary — Management of pancreatic fluid collections (drain only if symptomatic after 4-6 weeks of wall maturation) and summary of key principles for recurrent pancreatitis management.

Key claims

1:40Every ERCP carries a risk of post-ERCP pancreatitis, and islet cells are lost with every pancreatitis attack — Juan Gurria
1:57PRSS1 is the most common genetic mutation in pediatric pancreatitis and is a trypsinogen activator that activates trypsin inside the pancreas — Juan Gurria
2:12Cincinnati Children's genetic panel tests 10 different genetic markers for pancreatitis — Juan Gurria
2:17Genetic factors are changing the approach to pediatric chronic pancreatitis treatment — Juan Gurria
2:26Patients with more than 1 episode of acute pancreatitis or a first severe episode should undergo MRCP and genetic panel testing — Cecilia Gena
2:48There is currently no medication to mediate trypsin activation in genetic pancreatitis — Juan Gurria
3:09Frey procedure requires removing the top half of the pancreas to open the duct, resulting in loss of islet cells — Juan Gurria
3:19In patients with PRSS1 mutation, drainage procedures only temporize attacks by draining the duct but do not fix the underlying problem, as the parenchyma continues to be attacked by the mutation — Juan Gurria
3:37Genetic testing is essential before any resection procedure to avoid losing pancreatic cells in pathologies that will not benefit from resection and drainage — Cecilia Gena
4:09There is no set number of ERCPs that defines when to consider chronic pancreatitis; sooner referral is better for evaluation — Juan Gurria
4:16Surgical pancreatic intervention is not offered unless medical and endoscopic management have been maximized — Juan Gurria
4:31If a stent is placed and the patient continues to have pancreatitis, there is no reason to continue with ERCPs — Juan Gurria
4:37Endoscopic treatment should be attempted first, but if it fails, transfer to a specialized center that performs TPIAT — Cecilia Gena
4:58MRCP is the best non-invasive study for the pancreas, particularly with T2 sequences — Juan Gurria
5:07ERCP is more therapeutic than diagnostic — Juan Gurria
5:11Imaging approach starts with ultrasound, then CT, and MRCP with T2 sequences for better pancreatic anatomy visualization — Cecilia Gena
5:22Pancreatic fluid collections should be drained only if symptomatic once the wall is mature at 4 to 6 weeks — Juan Gurria
5:29Asymptomatic fluid collections without gastric outlet obstruction or pain will self-resolve and do not require drainage — Juan Gurria
5:35Antibiotics are not needed for pancreatic fluid collections — Juan Gurria
5:40Recurrent pancreatitis is a rare pathology that can lead to chronic pancreatitis and is associated with genetic mutations — Cecilia Gena
5:50If genetic mutations are confirmed, partial pancreatic resection (Frey procedure) should be avoided to prevent loss of pancreatic cells — Cecilia Gena
6:01If endoscopic approach fails, TPIAT should be considered sooner rather than later — Cecilia Gena

Cases discussed

0:397-year-old with acute recurrent pancreatitis who has undergone 7 ERCPs with stent placement

Points of disagreement

1:28Management approach for the 7-year-old case
- Speaker 5: Would perform Frey procedure (partial head pancreatectomy with duodenal preservation and pancreaticojejunostomy) on this patient
- Juan Gurria: Frey procedure inappropriate if genetic mutation present, as it only temporizes attacks by draining duct without fixing underlying problem, and results in loss of islet cells

Open questions

What is the optimal number of ERCPs before considering surgical referral?
Will medication to mediate trypsin activation in genetic pancreatitis become available in the future?

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Keywords

acute recurrent pancreatitis chronic pancreatitis post-ERCP pancreatitis gastric outlet obstruction pancreatic duct stricture ERCP balloon dilation stent placement Frey procedure partial head pancreatectomy pancreaticojejunostomy TPIAT total pancreatectomy with islet autotransplantation MRCP endoscopic ultrasound

Hashtags

#PediatricSurgery #Pancreatitis #GeneticMutations #ERCP #MRCP #TPIAT #IsletCellTransplant #ChronicPancreatitis #EndoscopicUltrasound #FluidCollections #CincinnatiChildrens #PediatricHealth #SurgeryEducation #MedicalResearch #ChildHealth #PancreaticSurgery #HealthCare #SurgicalManagement #PediatricCare #MedicalEducation #PediatricPancreatitis #GeneticTesting

Transcript

Global Cat MD along with Cincinnati Children's Hospital, sharing knowledge to improve child health around the globe. Hello pediatric surgery family. I'm Cecilia Gena, a research fellow from Cincinnati Children's Hospital Medical Center. Our 11th annual update course in pediatric surgery was held this past August. In this video, we are going to talk about management of recurrent pancreatitis, and for that we have Doctor Juan Gurria, a pediatric surgeon from Cincinnati Children's Hospital. So first we started with a case. 7 year old with acute recurrent pancreatitis, abdominal pain. It has a diagnosis of ARP referred to you with an ERCP showing a stricture in the head of the pancreas and a dilated duct distally. We've seen this multiple times, um, has had 7 ERCPs and a stent in the past. So, This is the ERCP. So we have a clear stricture in the area of the head of the pancreas and a dilated duct distal and you see clearly the branches. So, what is your plan? MRCP to evaluate for chronic changes, repeat ERCP balloon dilation and stent placement, MRCP and obtain genetics, or admin and plan for FRI procedure? The FR procedure is a partial head pancreatectomy with duodenal preservation and a pancreaticajeinostomy. And it's interesting to see this uh very divided um. MRC so the main is repeat ERCP. So keep doing it. We're 7 ERCPs in. The question is, when do you stop, right? Every time you get an, an ERCP you have a risk of getting post-E ERCP pancreatitis. It's low, right? But it's still a risk, and you lose eyelet cells with every attack. So we're losing cells down the road. And as he said, genetic is key, so it is really important to get a genetic panel. PRSS1 is the most common one, which is a trypsinogen activator. It activates trypsin inside the pancreas. There's CTRC, CFTR, um, you know, CPA1. There's a whole bunch of mutations that we now know. We, our gene, gene panel in Cincinnati runs 10 different genetic, um, uh, markers. So, that's how we're changing the approach to pediatric pancreatitis, chronic pan pancreatitis treatment because of the genetic factors. Awesome. So if a patient has more than 1 episode of acute pancreatitis or a first really bad episode. Of it, we should perform an MRCP and a genetic panel to rule out genetic anomalies. Now you have that patient that has the mutation that they're, they're trypsin activated. What's, how do you mediate that? Is there medication or is there another path that you can do to wonderful question. No, no, there's no, unfortunately we don't have that just yet. That's why I still have a job, but, uh, I hope, I hope some Monday we have, you know. I would do a pow on this kid. What's the downside of that? So, excellent excellent question. If there's a generic mutation, let's say there's a PRSS1 mutation, right? For a pistol, you have to like get the top of, the top half of the pancreas out to open the duct, right? Um, you, you throw, uh, some eyelet cells to the trash. Um, this patient most likely is gonna keep getting pancreatitis despite you draining the duct. The, the parenchyma is gonna keep getting attacked by the mutation. So, you're temporizing um the attack by draining the duct, uh, but you're not fixing the problem. Great, so genetics are very important before any resection procedure to avoid losing pancreatic cells in pathologies that will not benefit from a resection and drainage, but instead from an islet cells transplant. So I know the scenario. Pretty much points towards, OK, maybe recurrent or chronic pancreatitis, but after how many do you feel like, OK, this is what we're dealing with? 2, ERCPs, 3, when do you start thinking, considering that this might be a problem? That's a great question. We don't have a set number of ERCPs, so, uh, there's no set limit on that. The sooner the referral, the better for an evaluation. We don't offer, uh, to take care of the pancreas unless you've. Maximize medical and endoscopic management. If there's no other options and your endoscopic guy tells you, you know what, there's nothing for me to balloon dilate, open, drain, or anything. There's been a stent. Even with the stent, the patient keeps getting pancreatitis. There's no reason to keep going with ERCPs. So, do endoscopic treatment at first, but if it fails, transfer to a specialized center that does TPIAT. Or total pancreatectomy with eyelid autotransplantation. Now, what about imaging for these patients? So we use endoscopic ultrasound. An ultrasound and CT scan is imaging of choice once they come. MRCP is the best non-invasive study for pancreas by far, uh, with different uh uh T2 sequences. Um, um, they're great. An ERCP, of course, is more therapeutic than that. Diagnostic. Awesome. Start with ultrasound, then CT and for better see the pancreatic anatomy, MRCP with T2 sequences. Now, what about fluid collections? Once the, the wall is mature in 4 to 6 weeks, uh, if there's symptoms, drain it. If there's no symptoms, don't drain it. If the patient's not having gastric outlet obstruction or pain, there's no need to drain this. Um, it will, it will self resolve, uh, and, of course, there's no need for antibiotics. Also, time to summarize, recurrent pancreatitis is a rare pathology that can lead to chronic pancreatitis, and it is associated with genetic mutations. If genetic mutations are confirmed, we should avoid partially resecting pancreatic tissue as in a fright procedure to avoid losing pancreatic cells. The treatment should start with endoscopic approach, keeping in mind that if it fails, a TPI-AT should be considered sooner rather than later. For liquid collection, surgical treatment should be only done if the patient is symptomatic. I hope you enjoyed the video and thank you for watching. Don't forget to subscribe to the Stay Current MD YouTube channel. Follow our social media channels and download the Stay Current MD app for tons of content in pediatric surgery. Global Cat MD along with Cincinnati Children's Hospital, sharing knowledge to improve child health around the globe.

Comments

Loading comments…